Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03128866 · ClinicalTrials.gov registry record · Early Phase 1
Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery
A Early Phase 1 study of Pelvic Mass, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT03128866 is a Early Phase 1 study of Pelvic Mass that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03128866, a Early Phase 1 study of Pelvic Mass, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.
Conditions Studied
Interventions
- DRUG Tranexamic Acid
- PROCEDURE Hemipelvectomy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-05-19 |
| Est. Completion | 2026-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03128866
The ClinicalTrials.gov registry entry for NCT03128866 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pelvic Mass appearing as the primary indexed condition, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT03128866 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03128866 about?
NCT03128866 is a clinical study titled "Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery". This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.
What is the current status of trial NCT03128866?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2017-05-19. Estimated completion is 2026-05-31.
What conditions does trial NCT03128866 study?
This clinical trial studies the following conditions: Pelvic Mass.
What interventions are being tested in trial NCT03128866?
The interventions under investigation include: Tranexamic Acid (DRUG), Hemipelvectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03128866?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03128866 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.